Ca 15-3 in the follow-up of localised breast cancer (original) (raw)
Related papers
Ca 15-3 in the follow-up of localised breast cancer: a prospective study
European journal of cancer (Oxford, England : 1990), 2002
Altogether, 243 female breast cancer patients with localised disease diagnosed between 1991 and 1995 in the Tampere University Hospital area were followed prospectively after primary treatment until the first relapse. In the follow-up period, the serum tumour marker Ca 15-3 was analysed every 6 months to ascertain the validity of this marker in detecting the first relapse. The sensitivity and specificity of the test were analysed in different metastatic situations. During the 5 years of follow-up, 59 (24%) relapses were discovered. Ca 15-3 was elevated in 21/59 (36%) of the relapsed cases at least once. The 59 patients were subjected to 199 tests, of which 25 (13%) were positive. Among the 184 patients without recurrence, there were 6 (3%) with a positive Ca 15-3 level. The test failed to detect locoregional relapse or contralateral breast cancer. It was elevated in approximately half of bone-only metastases and in all of the liver-only metastases. In the pulmonary-only recurrences,...
The predictive of tumour markers CA 15-3, TPS and CEA in breast cancer recurrence
The Breast, 2000
The predictive values of tumour markers Carcinoma-Associated Antigen CA 15-3, Tissue Polypeptide Specific Antigen (TPS) and Carcinoembryonic Antigen (CEA) in recurrence of breast cancer are unclear. The aim of this study was to examine the predictive value of these markers in our population of 1448 patients with diagnosed breast cancer. Data and mean follow-up of 4.4 years were available on 1082 women of whom 277 had documented recurrence (mean follow up 5.7 years). The recurrence free patients had a mean follow up of 3.9 years.
European Journal of Cancer, 1994
The role of circulating tumour markers in providing prognostic information has been scarcely studied. We evaluated the prognostic significance of two mutinous markers: CA 15-3 and CA 125 in 115 breast cancer patients at first recurrence of disease. At diagnosis of advanced disease bone involvement was found in 64 patients, lung in 57, skin lymph nodes in 21, liver in 20, and brain in 5. Patients were recruited and treated in the same institution with conventional chemo-or endocrine therapy. The follow-up ranged from 3 to 54+ months (median 35). Serum samples were drawn at first recurrence of disease before the start of any endocrine and/or chemotherapy. Patients with CA 15-3 <30 U/ml survived signiticantly longer than those with CA 15-3 ~-30 U/ml (median 50+ versus 26 months, RO.02).
Breast Cancer Research and Treatment, 1995
To evaluate the utility of CEA and CA 15.3 for early diagnosis of recurrence, serial serum determinations of both antigens were performed in 1023 patients (follow-up: 1–10 years, mean 6.2 years) with primary breast cancer (CA 15.3 in 533 cases) and no evidence of residual disease (NED) after radical treatment (radical mastectomy or simple mastectomy and radiotherapy). 246 patients developed metastases during follow-up. Results: CEA and CA 15.3 were elevated (> 10 ng/ml or > 60 U/ml, respectively) prior to diagnosis in 40% (98/246) and 41% (37/91) of the patients with recurrence, with a lead time of 4.9 ± 2.2 and 4.2 ± 2.3 months, respectively. When patients with locoregional recurrences were excluded, sensitivity improved to 46% (CEA) and 54% (CA 15.3), and to 64% with both tumor markers (CEA and/or CA 15.3). Higher levels of both CEA and CA 15.3 at diagnosis of recurrence, higher sensitivity in early diagnosis of relapse, and a higher lead time were found in ER+ (CEA) or PgR+ patients (CA 15.3) than in those that were negative for these receptors in the primary tumor (p < 0.001). Specificity of the tumor markers was 99% for both CEA (777 NED patients) and for CA 15.3 (444 NED patients), respectively. In conclusion, CEA and CA 15.3 are useful tools for early diagnosis of metastases, mainly in those patients with ER+ or PR+ tumors.
Sensitivity of CA 15-3, CEA and serum HER2 in the early detection of recurrence of breast cancer
Clinical Chemistry and Laboratory Medicine, 2013
Background: The aim of this project was to investigate the sensitivity of CA 15-3, CEA and HER2 in the early diagnosis of metastatic breast cancer. Methods: Serial serum values of CA 15-3, CEA and HER2 were determined in 107 patients with recurrence after breast cancer. Fifteen of the patients had primary disseminated disease, nine patients only developed local recurrence during the follow-up period and the remaining 83 developed distant metastases. Results: In the group of patients with distant metastatic disease (n = 83), elevated serum levels of CA 15-3 (> 32.4 U/mL), CEA (> 2.5 μ g/L for non-smokers and > 10 μ g/L for smokers) and HER2 (> 15 μ g/L) were found in 49.4%, 38.6% and 32.5%, respectively, at the time of diagnosis of recurrence. CA 15-3 was significantly better than HER2 (p = 0.027). The most sensitive combination was obtained using CA 15-3/CEA (60.2%) or CA 15-3/HER2 (57.8%). Combining all three tumour markers raised the sensitivity to 63.9%. In the subgroup of patients with tissue HER2 + tumours, the sensitivity of HER2 increased to 55.6%. The best combination in this group was CEA/HER2 (66.7%). In the subgroup of patients with tissue HER2 − tumours, CA 15-3 was significantly better. The best combination was CA 15-3/HER2 or CA 15-3/CEA with a sensitivity of 55.8% and 59.6%, respectively. Conclusions: The combination of several tumour markers enhances the sensitivity for detection of metastatic breast cancer. We recommend HER2 or the combination of CEA and HER2 in tissue HER2 + and CA 15-3 or the combination of CA 15-3 and CEA in tissue HER2 − .
Cancer Letters, 1996
The potential usefulness of MCA, CA 15-3 and CEA in monitoring of breast cancer patients was evaluated in 135 female patients with histologically confirmed breast cancer. The patients were classified into two groups as follows: group of patients with no evidence of disease, NED; and group of patients with progressive disease, PD. In total, 2106 measurements of CEA, CA 15-3, and MCA were performed using an enzyme immunoassay. Serum levels of all three markers in the NED group differed significantly from those of patients with PD. The observed differences in the sensitivity and specificity of CEA, CA 1.5-3, and MCA tests were not significant. The serum concentrations of a particular marker correlated well with the concentrations of the other two markers, except when CEA was correlated with MCA or CA 15-3 in NED group patients. The elevation of tumor markers preceded by some 7 months the clinical evidence of dissemination, and marker levels reflected at a high percentage the response to therapy in PD patients. Therefore, this clinical study confirmed that MCA, CA 15-3 and also CEA are suited to discriminate between disease and disease-free periods, and also validated the usefulness of markers for treatment response monitoring. Keywords: Breast cancer; Carcinoembryonic antigen (CEA); Cancer-associated antigen 15-3 (CA 15-3); Mucin-like carcinoma-associated antigen (MCA); Follow-up 0304-3835/96/$12.00 Coovright 0
Serum Ca 15-3: A Useful Tumor Marker in the Prognostication of Locally Advanced Breast Cancer
Annals of Woman and Child Health, 2017
Locally advanced breast cancer (LABC) continues to be a common presentation of breast cancer worldwide. Various serum markers have been studied to know the behaviour, metastasis and prognosis of breast cancer without going through any invasive procedure. CA 15-3 measures the protein product of the MUC 1 gene and is the most commonly used serum marker in breast cancer. The main use of serum CA 15-3 is monitoring therapy response and elevated levels are associated with metastatic disease and in non-metastatic patients, it is associated with poor prognosis. The aim of the study was to know the role of serum CA 15-3 level in diagnosis, prognosis and therapy response in patients with locally advanced breast cancer and to assess its relationship with other variables like tumor size, microscopic grade, nodal burden and Ki-67 antigen expression. Serum CA 15-3 levels significantly decreased after neo-adjuvant chemotherapy and mastectomy and it remained elevated in patients with suspected or hidden metastasis. Serum CA 15-3 levels exhibited positive statistically significant correlation with tumor size.
Usefulness of serum CA 15.3 and histopathological prognostic indices in breast cancer
Indian Journal of Clinical Biochemistry, 2005
Prognostic factors influence the modality and course of therapy in breast cancer. These include beth histopathological and biochemical variables. This study was aimed to find out if any correlation exists between the biochemical tumor marker-serum CA 15.3, and the lymph node staging of Nottingham's Prognostic Index (NPI). It was observed that serum CA 15.3 showed a statistically significant correlation with lymph node staging of NPI. Therefore it is concluded that CA 15.3 can be utilized as a useful prognostic marker, particulady in cases where histopathological variables such as tumor size and grade have been altered by preoperative chemotherapy.
Analysis of tumour marker CA 15-3 in breast cancer following surgery
International Surgery Journal, 2016
Background: CA 15-3 is a mucin belonging to a large family of glycoprotein's encoded by the MUC1 gene. Elevated pre-operative CA 15-3 level is directly related to tumour burden and independent prognostic factors for breast cancer. It could be considered for clinical use such as predicting patient outcome and determining adjuvant treatment for better outcome. Methods: In this study 30 female patients diagnosed with carcinoma breast were staged according to TNM classification and Serum CA 15-3 level were assayed by ELISA method before surgery and one month after surgery. Results: In present study on comparing preoperative serum CA 15-3 level to the postoperative level, it was found that CA15-3 level falls following breast surgery. Patients with Stage I showed fall in CA 15-3 level and came to normal level i.e from 37.8 ±6.9 U/mL to 30.3±3.1u/ml. In Stage II there was also fall in CA 15-3 level in all patients but few patients Ca 15-3 level was still above normal i.e from 44.98±14.32 U/mL to 34.98±13.95/ml. In Stage III patients few showed fall in CA 15-3 levels but none came below normal whereas few patients showed rise in CA 15-3 level postoperatively compared to its preoperative level (p<0.001). Conclusions: Serial measurement of CA 15-3 are more important to detect recurrence or metastasis at any time after treatment but even single postoperative CA 15-3 value together with preoperative value is of great importance. If postoperative CA 15-3 level remains stable or increases, it indicates chances of recurrence.
British journal of cancer, 1997
In order to study the relationship between circulating levels of CA 15-3 and the disease extent in predicting survival, we prospectively followed 312 breast cancer (BC) patients, from October 1988 to March 1995, from the time of first relapse. CA 15-3 values were assessed before treatment onset. Disease extent was defined as the percentage of liver or lung involvement and the number of bone segments positive at scintigraphy. The covariates were primary tumour characteristics (T, N and hormone receptor status) and patient characteristics at recurrence (menopause, performance status and age). Higher CA 15-3 serum levels were found in patients with visceral metastases or with pleural effusion. A logistic regression model selected disease extent in liver, lung and bone as independent variables for the determination of abnormal CA 15-3 values. Univariate survival analysis confirmed the positive prognostic influence of low CA 15-3 serum levels, absence of visceral metastases and the prese...